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INTRODUCTION
Advances in care and treatment have improved opportunities for health, quality of life and longevity among persons with HIV, as well as opportunities for preventing infections at the population level [1] [2] [3] [4] . The challenge for realizing the individual and public health benefits of HIV treatment resides in ensuring a continuum of HIV care, from timely diagnosis to prompt linkage to care, and from linkage to retention in care over time [5, 6] , with consistent access and adherence to antiretroviral medications [7] [8] [9] [10] [11] . In recognition of this challenge, the 2010 U.S.
National HIV/AIDS Strategy (NHAS) issued a call to increase HIV care access and enhance outcomes along the care continuum, with specific targets to be met by 2015 [12] .
National estimates have suggested suboptimal population-level care continuum outcomes, with 72%-80% of those diagnosed with HIV promptly linked to care, 45-59% retained in care, and 24%-43% virally suppressed [13] [14] [15] [16] [17] . Factors associated with suboptimal HIV health care utilization and clinical outcomes include black or Latino race/ethnicity [15, 17, 18] , younger age [17] [18] [19] , lower income [19] , non-AIDS status at baseline [17] [18] [19] , mental health or substance use disorders [15, 17, [20] [21] [22] [23] , stigma or low social support [24] , non-U.S. country of birth [15, 18] and unstable housing [25, 26] . However, there remains little evidence on how best to address these disparities, or which interventions are broadly capable of improving both care utilization and specific biomedical outcomes, such as viral load (VL) suppression [27] , in real-world service settings [28] [29] [30] [31] . We report here on a large-scale, multi-site evaluation of short-term (one-year) care engagement and VL suppression outcomes, as well as subgroup variations in those outcomes, among clients enrolling in a comprehensive HIV care coordination intervention delivered in New York City (NYC). 
Study Population (Figure 1)
We conducted a pre-post retrospective cohort evaluation of CCP intervention effectiveness using individuals as their own controls. The intent-to-treat analysis examined all CCP clients who met inclusion criteria, regardless of service activity or duration of CCP exposure. Included clients were enrolled in the CCP by March 31, 2011 and matched to the Registry, based on a previously described deterministic algorithm [34] . Additionally, to ensure adequate follow-up time, we excluded clients who died within 12 months of enrollment. All clients in the analysis were categorized as either newly diagnosed (diagnosed with HIV in the 12 months prior to enrollment) or previously diagnosed (diagnosed more than 12 months prior to enrollment). To explore outcome differences among the previously diagnosed by care status immediately prior to enrollment in the CCP, those clients were further classified as current to care at baseline (with a A c c e p t e d M a n u s c r i p t 7
Statistical Methods
For each outcome, proportions were computed for the 12-month period before CCP enrollment (previously diagnosed only) and the 12-month period after CCP enrollment (all eligible CCP clients). Relative risks (RRs) were used to compare post-enrollment with pre-enrollment proportions for EiC and VLS among previously diagnosed clients, both overall and stratified within client subgroups according to: baseline care status, sociodemographic characteristics (sex, race/ethnicity, age, primary language spoken, insurance status, housing status, income level, and country of birth), and clinical/treatment factors (ART status at enrollment, year of HIV diagnosis, viral suppression at enrollment, and CD4 cell count at enrollment). To account for correlation in the repeated-measure, pre-post design, we used Generalized Estimating Equations (GEE) to estimate pre-post RRs and 95% confidence intervals (CIs). All analyses were conducted using SAS® software version 9.2.
Ethics Statement
This study was approved by the NYC DOHMH and the City University of New York School of Public Health (CUNY SPH) Institutional Review Boards. of the clients in this sample had irregular care patterns; 41.3% had adherence issues; 13.0% were newly diagnosed; 10.7% were lost to care/never in care; 9.2% were starting a new ART regimen; and 9.0% had treatment failure or ART resistance. Among previously diagnosed clients, the proportion with EiC (Table 2 and Figure 2 ) increased from 73.7% to 91.3% (RR EiC =1.24, 95% CI: 1.21-1.27) and the proportion with VLS (Table 3 and Figure 3 ) increased from 32.3% to 50.9% (RR VLS =1.58, 95% CI: 1.50-1.66) from the pre-to the post-CCP enrollment period. While gains were observed for all previously diagnosed CCP clients, those out of care at CCP enrollment contributed most to overall improvements. However, even among those current to care, significant improvements were observed for both outcomes In analyses stratified by baseline demographic and clinical/treatment variables, the significant overall improvements observed for both study outcomes generally held across the examined subgroups, except for those clients with baseline CD4 ≥500 (VLS only), baseline viral load ≤200, or "other/unknown" race (EiC only). Within stratifying variables, the greatest relative improvements were observed among those under age 45, diagnosed after 2004, without an antiretroviral prescription at enrollment, born male (EiC only), making <$9,000/year (EiC only), uninsured (EiC only), homeless (EiC only), virally unsuppressed at enrollment (EiC only), and having CD4 <200 at enrollment (VLS only). Stratifying by agency of first CCP enrollment, statistically significant improvements were observed for EiC at 25 (89%) and for VLS at 21 (75%) of the 28 CCP agencies.
RESULTS

Sample Characteristics
CCP Enrollment Status and Duration at 12-month Follow-up
As of 12 months post-enrollment, 61.3% of clients were still enrolled. Among the 38.7% with a program closure during the 12-month follow-up period, the median CCP enrollment was 197 days or 0.54 years (IQR 117-278 days), and 6.9% had graduated due to achieving selfsufficiency (defined as meeting specific criteria including ≥95% treatment adherence, reduced hospitalizations, and maintenance of scheduled appointments). Other reasons for closure included: discharge based on program requirements (e.g., due to client non-participation, staff safety concerns or income or residence-based ineligibility) (47.2%); loss to follow-up (19.0%); relocation out of neighborhood (7.2%), or transfer of care to another provider (19.5%). A check of both outcomes by enrollment duration confirmed significant relative risks even for those enrolled <6 months. Though the 95% confidence intervals overlapped, relative risks trended Nonetheless, the outcome variations by baseline care status in our study suggest the potential value of even more specifically prioritizing for CCP enrollment those never in care or out of care for at least six months, as well as those newly diagnosed. Differences found in the degree of improvement post-CCP enrollment by demographic characteristics suggest a higher potential impact among low-income, uninsured, unstably housed, and younger populations, while differences by clinical/treatment factors suggest a higher potential impact for those with lower CD4, unsuppressed viral load, and/or no current prescription for ART at enrollment. These differences (even among groups sharing significant improvements) will inform future phases of effectiveness and cost-effectiveness research and guide future applications of the program model. As recent reviews have described, complex intervention designs, employing multiple evidenceinformed strategies and means of service delivery (e.g., home-based, clinic-based, and via telecommunications) appear to represent the direction of retention/adherence support services evolution, and may be essential for addressing the multiple impediments to accessing and maintaining HIV primary care and antiretroviral treatment [30, 38] . Further research is needed, however, to investigate the relative effectiveness and cost-effectiveness of different components of such complex interventions, to assess the cost-effectiveness of retaining all elements (vs. a pared-down package), and to continue to examine outcomes for longer periods post-enrollment, given that interventions to improve HIV care outcomes often show a tapering of the effect with distance in time from the intervention (e.g.,
[38]).
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Limitations and Strengths
As an observational study based in a real-world setting, this study has certain limitations. For example, given that many elements of the CCP intervention are delivered simultaneously or based on client indication, it is challenging to assess the relative contributions of specific components of the CCP intervention. We also could not account for exposure to other contemporaneous interventions or environmental changes external to the CCP, which may have partially driven some of the improvements observed. In addition, due to CCP selection criteria, there is the potential that previously diagnosed individuals may have come into the program at a time when they were more vulnerable to (and expressive of) suboptimal outcomes than at other times in their post-diagnosis history. However, we were able to measure client health at baseline via clinical markers, and we observed significant improvements in EiC and VLS in all CD4 categories except CD4>500 cells/μL (accounting for 19.0% of the sample).
The selection of clients based on known care and treatment barriers may in part explain the programmatic closure of over a third of the sample during the follow-up period, generally for reasons other than graduation. However, the significant improvements observed in this analysis even for those enrolled less than six months, as well as the small group of clients graduating during the follow-up period, suggest that some individuals obtain what they need from the program in under a year. The upward trend in relative risks with increased enrollment duration suggests that exposure time does matter, and warrants further dose-response analyses.
Regarding data sources, the use of laboratory data from a surveillance registry may result in under-or over-estimation of engagement in HIV primary care. Some primary care visits may not be accompanied by laboratory tests, and some laboratory tests may be ordered outside of the A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 22 2 Engagement in care is defined as ≥2 CD4 or viral load (VL) tests ≥90 days apart, with ≥1 test in each half of the 12-month period specified. 3 12 months prior to the client's CCP enrollment window (defined as the 31 days leading up to and including date of enrollment). 4 Out of care: CCP clients who were diagnosed more than 12 months prior to their CCP enrollment window and had no evidence of primary care (CD4 or VL test) in the 6 months prior to their CCP enrollment window. 5 Current to care: CCP clients who were diagnosed more than 12 months prior to their CCP enrollment window and had evidence of primary care in the 6 months prior to their CCP enrollment window. 6 Median VL, viral suppression, median CD4, and CD4 at enrollment are determined by client's most recent CD4 or VL test occurring in the 6 months prior to their enrollment window. 7 Clients who did not have a VL test reported during the 6 months prior to their enrollment window were categorized as unsuppressed. 2 Viral load suppression is defined as VL ≤200 copies/mL on most recent test in the second half of the 12-month period specified. 3 12 months prior to the client's CCP enrollment window (defined as the 31 days leading up to and including date of enrollment). 4 Out of care: CCP clients who were diagnosed more than 12 months prior to their CCP enrollment window and had no evidence of primary care (CD4 or VL test) in the 6 months prior to their CCP enrollment window. 5 Current to care: CCP clients who were diagnosed more than 12 months prior to their CCP enrollment window and had evidence of primary care in the 6 months prior to their CCP enrollment window. 6 Median VL, viral suppression, median CD4, and CD4 at enrollment are determined by client's most recent CD4 or VL test occurring in the 6 months prior to their enrollment window. 7 Clients who did not have a VL test reported during the 6 months prior to their enrollment window were categorized as unsuppressed. CCP enrollment, and thus were not engaged or suppressed at baseline; no post-vs. pre-relative risk can be constructed. 1 VLS is defined as VL ≤200 copies/mL on most recent test in the second half of the 12-month period specified. 2 Newly diagnosed: CCP clients who were diagnosed in the 12 months prior to their CCP enrollment window (defined as the 31 days leading up to and including date of enrollment). 3 Previously diagnosed: CCP clients who were diagnosed more than 12 months prior to their CCP enrollment window (defined as the 31 days leading up to and including date of enrollment). 4 Out of care: previously diagnosed CCP clients who had no evidence of primary care in the 6 months prior to their CCP enrollment window. 5 Current to care: previously diagnosed CCP clients who had evidence of primary care in the 6 months prior to their CCP enrollment window.
